[The impact of hormone replacement therapy applied in women with varicose vein on changes in coagulation and fibrinolysis].
In fifty two postmenopausal women (study group: n = 20 with varicose vein; controls: n = 32) with climacteric symptoms some changes in fibrinolytic and coagulative parameters were measured during six months of HRT consisted of transdermal oestradiol (17 beta-E2) and oral medroxyprogesterone acetate (MPA). Additionally, sonographic examinations of the venous system of pelvis minor and low extremities were performed three times in every women--at baseline, in the 3rd and the 6th month of the trial. In the 3rd month the varicose vein group exhibited lowered INR and t-PA, but the in 6th month increased D-dimer as compared to the controls. No sonographic signs of venous thromboembolism were detected.


CONCLUSIONS
1) Postmenopausal varicose vein women taking combined HRT (17 beta-E2 plus MPA) are on slightly increased additional risk of venous thromboembolism, 2) in monitoring of these patients sonographic evaluation of the venous system of low extremities and pelvis minor and well as D-dimer in blood serum should be done.
Stachowiak
Grzegorz
G
Klinika Ginekologii i Chorób Menopauzy Instytutu Centrum Zdrowia Matki Polki w Łodzi.
Połać
Ireneusz
I
Stefańczyk
Ludomir
L
Owczarek
Danuta
D
Jedrzejczyk
Sławomir
S
Pertyński
Tomasz
T
D000279:Administration, Cutaneous; D003276:Contraceptives, Oral / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D035002:Lower Extremity / Q000098:blood supply; D008525:Medroxyprogesterone / Q000008:administration & dosage*; D008875:Middle Aged; D010388:Pelvis / Q000098:blood supply; D017698:Postmenopause / Q000502:physiology*; D014463:Ultrasonography; D014648:Varicose Veins / Q000000981:diagnostic imaging*
D003276:Contraceptives, Oral; D004967:Estrogens; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D008525:Medroxyprogesterone